论文部分内容阅读
目的分析阿托伐他汀对慢性心力衰竭(心衰)患者防治作用的有效性。方法 200例慢性心衰患者,按照随机原则分成对照组和实验组,各100例。对照组患者采用常规心衰治疗,实验组患者则在对照组患者治疗的基础上给予阿托伐他汀治疗。比较治疗前后两组患者的微循环积分和临床细胞因子水平。结果治疗后实验组患者的微循环积分[总积分(1.51±0.52)分、襻周积分(0.83±0.31)分、管襻积分(0.56±0.21)分、流动积分(1.32±0.09)分]、血清细胞因子水平[肉皮素1(ET)(75.42±25.07)mg/ml、可溶性CD40配体(Scd40L)(5.92±1.93)mg/ml、血管内皮生长因子(VEGF)(54.31±18.07)pg/ml、降钙素基因相关肽(CGRP)(95.28±31.82)mg/ml]均显著低于对照组[(2.42±0.77)、(1.46±0.50)、(1.05±0.37)、(2.01±0.27)分,(97.63±32.47)mg/ml、(9.52±3.21)mg/ml、(75.41±25.12)pg/ml、(105.83±35.31)mg/ml](P<0.05)。结论临床中针对慢性心衰患者,在常规心衰治疗的基础上给予阿托伐他汀治疗能对患者的临床诊断指标进行有效改善,降低致病细胞因子水平,对于防治慢性心衰患者具有非常显著的作用。
Objective To analyze the effectiveness of atorvastatin in the prevention and treatment of chronic heart failure (CHF). Methods 200 cases of chronic heart failure patients were divided into control group and experimental group according to the randomized principle, each 100 cases. Patients in the control group were treated with conventional heart failure and patients in the experimental group were given atorvastatin on the basis of treatment in the control group. Microcirculation scores and clinical cytokine levels were compared between the two groups before and after treatment. Results After the treatment, the patients in the experimental group had significantly higher scores of microcirculation score (1.51 ± 0.52), 襻 week integral (0.83 ± 0.31), 管 襻 integral (0.56 ± 0.21), flow integral (1.32 ± 0.09) Serum levels of cytokines [VEGF (54.31 ± 18.07) pg / ml, IC50 of 75.42 ± 25.07 mg / ml, Scd40L of 5.92 ± 1.93 mg / ml and calcitonin gene related peptide (CGRP) (95.28 ± 31.82) mg / ml were significantly lower than those in the control group [(2.42 ± 0.77), (1.46 ± 0.50), (1.05 ± 0.37) and (2.01 ± 0.27) (97.63 ± 32.47) mg / ml, (9.52 ± 3.21) mg / ml, (75.41 ± 25.12) pg / ml, (105.83 ± 35.31) mg / ml] Conclusions In patients with chronic heart failure, atorvastatin treatment on the basis of conventional heart failure can effectively improve the clinical diagnosis of patients and reduce the level of pathogenic cytokines, which is very significant for the prevention and treatment of chronic heart failure Role.